Drugs / Xaluritamig
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT07493512 | Apr 2026 → Jul 2030 expected | castration-resistant prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07297979 | Apr 2026 → May 2030 expected | Ewing sarcoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT07140900 | Oct 2025 → Mar 2028 expected | metastatic prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06613100 | Nov 2024 → Jan 2027 expected | prostate cancer | Amgen | Recruiting | No outcome recorded |
| Phase 1 | NCT06555796 | Sep 2024 → Mar 2027 expected | prostate cancer | Amgen | Active not recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT07213674 | Nov 2025 → Jan 2030 expected | prostate carcinoma | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06691984 | Dec 2024 → Jan 2029 expected | castration-resistant prostate carcinoma | Amgen | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-10-16 | Amgen | Results AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023 amgen.com ↗
Early-Stage Results for AMG 509 (xaluritamig) Illustrate Expanding Potential of Amgen 's T-Cell Engagers in mCRPC |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-10-16 | Amgen | AMGEN TO PRESENT NEW RESEARCH FROM ONCOLOGY PORTFOLIO AND PIPELINE AT ESMO 2023 amgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xaluritamig | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07493512 ↗ |
| Route | Intravenous | “IV infusion” NCT06555796 ↗ |